Pfizer calls Novo Nordisk bid on Metsera ‘reckless’
MLex Summary: Pfizer called Novo Nordisk’s bid to buy Metsera for $9.1 billion a “reckless and unprecedented proposal,” arguing that it’s “structured in a way to circumvent antitrust laws and carries...To view the full article, register now.
Already a subscriber? Click here to view full article